Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
20–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients will be eligible for enrolment into the study (Visit 1) if they fulfil all of the following criteria:
Provision of signed Informed Consent
Primary hypertension, untreated or treated with a maximum of 2 antihypertensive drugs (substances), which the patient and the physician are willing to withdraw at enrolment and replace with placebo.
Mean sitting DBP 90-114 mmHg (value calculated in the eCRF) at Visits 1 and 2
Patients will be eligible for randomisation (Visit 4) if they fulfil the following criterion:
Mean sitting DBP of 90-114 mmHg (value calculated in the eCRF) at the end of the 4-week single-blind placebo run-in period. The run-in period should not be shorter than 4 weeks.
You may not be if
Pregnant or lactating women, or women of childbearing potential not practising an adequate method of contraception eg, intrauterine device, oral contraception or progesterone implant. Pregnancy must be excluded by a negative pregnancy test at Visit 1.
Secondary or malignant hypertension
Sitting SBP of 180 mmHg or more
Myocardial infarction, stroke, coronary bypass surgery or transient ischaemic attack within 6 months before enrolment
Angina pectoris requiring more treatment than short-acting nitrates
Chronic use of NSAIDs
Aortic or mitral valve stenosis
Cardiac failure requiring treatment
Cardiac arrhythmia requiring treatment
Gout
Renal artery stenosis or kidney transplantation
Intravascular volume depletion
Hypersensitivity to any component of the investigational products or to any sulphonamide derived drugs
Concomitant disease which may interfere with the assessment of the patient
Past or present alcohol or drug abuse, or any condition associated with poor compliance that in the opinion of the investigator might affect the patient's participation in the study
Chronic liver disease
Concomitant or previous treatment with any other investigational drug within 20 days of enrolment
Previous enrolment in the present study
Clareo Health | Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
